Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: Involvement of cell line-specific apoptotic mechanisms

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2703-2714

  Rao, Prema S ^a   Satelli, Arun ^a   Moridani, Majid ^a   Jenkins, Marjorie ^a   Rao, U Subrahmanyeswara ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

ABCG2; drug transporters; luteolin; multidrug resistance; P glycoprotein

Indexed keywords

ATR PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CASPASE 7; CHECKPOINT KINASE 2; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEOLIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CASPASE 7; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUTEOLIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES;

EID: 84859160437     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26308     Document Type: Article

References (50)

1. Tait SW, Green DR,. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-32.
2. Thorburn A,. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-44.
3. MacFarlane M,. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139: 89-97.
4. Gyrd-Hansen M, Meier P,. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-74.
5. Hunter AM, LaCasse EC, Korneluk RG,. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68.
6. Varfolomeev E, Vucic D,. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008; 7: 1511-21.
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD,. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-70.
8. van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, Bladeren PJ, Rietjens IM, Cnubben NH,. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005; 69: 699-708.
9. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT,. The antitumor activities of flavonoids. In Vivo 2005; 19: 895-909.
10. Imai Y, Tsukahara S, Asada S, Sugimoto Y,. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004; 64: 4346-52.
11. Shi RX, Ong CN, Shen HM,. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 2005; 65: 7815-23.
12. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T,. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 2005; 333: 833-8.
13. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC, Tighiouart M, Khuri FR, Chen ZG, Shin DM,. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 2010; 285: 34557-65.
14. Alvarez AI, Real R, Perez M, Mendoza G, Prieto JG, Merino G,. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2009; 99: 598-617.
15. Brand W, Schutte ME, Williamson G, van Zanden JJ, Cnubben NH, Groten JP, van Bladeren PJ, Rietjens IM,. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 2006; 60: 508-19.
16. Morris ME, Zhang S,. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006; 78: 2116-30.
17. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH,. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992; 52: 6175-81.
18. Fairchild CR, Moscow JA, O'Brien EE, Cowan KH,. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol Pharmacol 1990; 37: 801-9.
19. Satelli A, Rao PS, Thirumala S, Rao US,. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 2010; in press.
20. Rao PS, Govindarajan R, Mallya KB, West W, Rao US,. Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein. Clin Cancer Res 2005; 11: 5833-9.
21. Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE,. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 2004; 43: 9448-56.
22. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K,. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002; 8: 22-8.
23. Steinfelder HJ, Quentin I, Ritz V,. A fast and sensitive technique to study the kinetics and the concentration dependencies of DNA fragmentation during drug-induced apoptosis. J Pharmacol Toxicol Methods 2000; 43: 79-84.
24. Rao PS, Mallya KB, Srivenugopal KS, Balaji KC, Rao US,. RNF2 interacts with the linker region of the human P-glycoprotein. Int J Oncol 2006; 29: 1413-9.
25. Rao US, Scarborough GA,. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 1994; 45: 773-6.
26. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I,. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 1992; 89: 8472-6.
27. Rao US,. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J Biol Chem 1995; 270: 6686-90.
28. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA,. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267: 4854-8.
29. Favaro G, Clementi C, Romani A, Vickackaite V,. Acidichromism and ionochromism of luteolin and apigenin, the main components of the naturally occurring yellow weld: a spectrophotometric and fluorimetric study. J Fluoresc 2007; 17: 707-14.
30. Cheng AC, Huang TC, Lai CS, Pan MH,. Induction of apoptosis by luteolin through cleavage of Bcl-2 family in human leukemia HL-60 cells. Eur J Pharmacol 2005; 509: 1-10.
31. Farrow SN, Brown R,. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 1996; 6: 45-9.
32. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R,. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 2005; 26: 1978-87.
33. Kim SJ, Hwang SG, Shin DY, Kang SS, Chun JS,. p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 2002; 277: 33501-8.
34. Abraham RT,. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-96.
35. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C,. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289-300.
36. Janicke RU,. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009; 117: 219-21.
37. Priyadarsini RV, Vinothini G, Murugan RS, Manikandan P, Nagini S,. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr Cancer 2011; 63: 218-26.
38. van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens IM, Cnubben NH,. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem Pharmacol 2005; 69: 1657-65.
39. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Matsui H, Sakai T,. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005; 24: 7180-9.
40. Spencer JP, Chowrimootoo G, Choudhury R, Debnam ES, Srai SK, Rice-Evans C,. The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Lett 1999; 458: 224-30.
41. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ,. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996; 2: 659-68.
42. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y,. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 2007; 71: 1381-8.
43. Fang J, Zhou Q, Shi XL, Jiang BH,. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007; 28: 713-23.
44. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M, Sata M,. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006; 66: 4826-34.
45. Chen JS, Agarwal N, Mehta K,. Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 2002; 71: 237-47.
46. Cuadrado A, Nebreda AR,. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403-17.
47. Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, Bachs O,. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 2000; 275: 35091-7.
48. Sethi G, Sung B, Aggarwal BB,. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008; 233: 21-31.
49. Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC, Borner MM,. Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst 2000; 92: 1535-6.
50. Ogretmen B, Safa AR,. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997; 14: 499-506.